Physician profile
Omer Junaidi
NPI 1457435331
$1,216.34
in general payments reported to CMS, 2019-2025
10 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.72 · 2020: $18.07 · 2022: $120 · 2023: $190 · 2024: $309 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $262.80 | 2024-2025 | Resmetirom, Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $237.25 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $222.98 | 2019-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $119.85 | 2022 | |
| Abbvie INC. | $108.99 | 2023 | |
| Erbe USA INC | $80.77 | 2023 | Erbe Apc3 |
| Veloxis Pharmaceuticals, INC. | $63.34 | 2025 | Envarsus |
| Mallinckrodt Hospital Products INC. | $62.99 | 2024-2025 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.21 | 2024-2025 | Xifaxan |
| Davol INC. | $16.16 | 2024 | Arista Ah Flexitip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Junaidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.